{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:29Z","timestamp":1790759549068,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.bbmt.2014.03.016","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T01:47:33Z","timestamp":1396576053000},"page":"979-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Zaid","family":"Al-Kadhimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zartash","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Ayash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voravit","family":"Ratanatharathorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.03.016_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-011-1299-8","article-title":"Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials","volume":"91","author":"Chang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbmt.2010.07.022","article-title":"One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing","volume":"17","author":"Valcarcel","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib3","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib4","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib5","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib6","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","article-title":"Immunosuppressive activity of mycophenolate mofetil","volume":"685","author":"Eugui","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbmt.2014.03.016_bib8","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V94.7.2523.419k18_2523_2529","article-title":"Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant","volume":"94","author":"Storb","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib9","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-6632.2001.tb03601.x","article-title":"Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect","volume":"938","author":"Feinstein","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbmt.2014.03.016_bib11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bmt.1704493","article-title":"Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies","volume":"33","author":"Rodriguez","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A\u00a0prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bbmt.2005.03.006","article-title":"A\u00a0phase I\/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation","volume":"11","author":"Nash","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.bmt.1704640","article-title":"Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation","volume":"34","author":"Mohty","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/01.TP.0000129809.09718.7E","article-title":"A\u00a0comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation","volume":"78","author":"Le Blanc","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.03.016_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbmt.2005.10.012","article-title":"Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation","volume":"12","author":"Nieto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2009.04.004","article-title":"Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality","volume":"15","author":"Sabry","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/bmt.2010.167","article-title":"Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases","volume":"46","author":"Zohren","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A\u00a0randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib22","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.bbmt.2012.06.004","article-title":"Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation","volume":"18","author":"Al-Kadhimi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib24","first-page":"49","article-title":"Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC)","volume":"9","author":"Ratanatharathorn","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbmt.2006.02.009","article-title":"High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"12","author":"Law","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib27","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/bmt.2009.343","article-title":"Sirolimus for treatment of steroid-refractory acute graft-versus-host disease","volume":"45","author":"Hoda","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib28","doi-asserted-by":"crossref","unstructured":"Cutler C, Logan BR, Nakamura R, et\u00a0al. Tacrolimus\/sirolimus vs. tacrolimus\/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. ASH Annual Meeting Abstracts Blood 2012;120:739.","DOI":"10.1182\/blood.V120.21.739.739"},{"key":"10.1016\/j.bbmt.2014.03.016_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12185-011-0888-6","article-title":"Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation","volume":"94","author":"Wakahashi","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.bbmt.2013.04.026","article-title":"Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation","volume":"19","author":"McDermott","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib31","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1016\/j.transproceed.2009.06.231","article-title":"Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease","volume":"41","author":"Nishikawa","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2014.03.016_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bmt.1705148","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease","volume":"36","author":"Yanada","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1200\/JCO.2004.06.102","volume":"22","author":"Ringden","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1704108","article-title":"G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV","volume":"32","author":"Remberger","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V96.1.80","article-title":"A\u00a0randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation","volume":"96","author":"Bishop","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.bmt.1702816","article-title":"Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation","volume":"27","author":"Ozcan","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib38","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2005-07-2661","article-title":"Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation","volume":"107","author":"Khoury","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib39","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1182\/blood.V97.11.3405","article-title":"Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors","volume":"97","author":"Przepiorka","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1702579","article-title":"Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation","volume":"26","author":"Stinson","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1704228","article-title":"The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis","volume":"32","author":"Ho","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib42","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib45","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib46","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.bbmt.2011.07.008","article-title":"Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies","volume":"17","author":"Passweg","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib47","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2006-07-034348","article-title":"Hyperacute GVHD: risk factors, outcomes, and clinical implications","volume":"109","author":"Saliba","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib48","first-page":"16","article-title":"Acute graft-versus-host disease. The incidence and risk factors","volume":"11","author":"Wojnar","year":"2006","journal-title":"Ann Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib49","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","article-title":"Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis","volume":"117","author":"Arora","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.03.016_bib50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.03.016_bib51","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.03.016_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114001657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114001657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:14Z","timestamp":1761058094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1083879114001657"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}